The U.S.’s supply of an antibody drug found to reduce the risk of severe Covid-19 disease could run out in August, and sales could shift to the commercial market unless Congress agrees on more pandemic funding
Last doses of the drug, one of few found to reduce risk of severe disease even after Omicron, will be used up in August without more pandemic funding, officials say
The FDA has cleared Merck’s new Covid-19 therapy molnupiravir, the latest antiviral that adults can take at home to avoid severe disease. WSJ’s Daniela Hernandez explains the science behind the new drug. Photo: Merck
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: